Arecor

Arecor

Advancing today’s therapies to enable healthier lives

2018
First invested

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

Meet the team

Related articles

The time to put the spotlight on Healthcare is now

As Covid-19 continues to dominate the global agenda, early-stage UK technology companies in the healthcare and...

Downing LLP launches 'knowledge intensive' EIS fund to fuel entrepreneurial healthcare businesses in wake of Covid-19

Specialist tax-efficient investment manager Downing LLP is pleased to announce the launch of a new Enterprise ...

How to survive and thrive in 2021 as a VC firm according to Downing Ventures - article

In 2021, it has never been more important for venture capital firms to be able to differentiate.